CiprofibrateCAS# 52214-84-3 |
- CFM 1571 hydrochloride
Catalog No.:BCC5924
CAS No.:1215548-30-3
- A 350619 hydrochloride
Catalog No.:BCC5939
CAS No.:1217201-17-6
- BAY 41-2272
Catalog No.:BCC7932
CAS No.:256376-24-6
- Riociguat
Catalog No.:BCC1899
CAS No.:625115-55-1
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 52214-84-3 | SDF | Download SDF |
| PubChem ID | 2763 | Appearance | Powder |
| Formula | C13H14Cl2O3 | M.Wt | 289.15 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Win35833 | ||
| Solubility | DMSO : ≥ 100 mg/mL (345.84 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid | ||
| SMILES | CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CC2(Cl)Cl | ||
| Standard InChIKey | KPSRODZRAIWAKH-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C13H14Cl2O3/c1-12(2,11(16)17)18-9-5-3-8(4-6-9)10-7-13(10,14)15/h3-6,10H,7H2,1-2H3,(H,16,17) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Ciprofibrate is a peroxisome proliferator-activated receptor agonist.
Target: PPAR
Ciprofibrate is a hypolipidemic compound that can induce proliferation of peroxisomes in liver cells of rats. Known to be a PPARα (peroxisome proliferator-activated receptor α) agonist [1, 2]. References: | |||||
Ciprofibrate Dilution Calculator
Ciprofibrate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.4584 mL | 17.2921 mL | 34.5841 mL | 69.1683 mL | 86.4603 mL |
| 5 mM | 0.6917 mL | 3.4584 mL | 6.9168 mL | 13.8337 mL | 17.2921 mL |
| 10 mM | 0.3458 mL | 1.7292 mL | 3.4584 mL | 6.9168 mL | 8.646 mL |
| 50 mM | 0.0692 mL | 0.3458 mL | 0.6917 mL | 1.3834 mL | 1.7292 mL |
| 100 mM | 0.0346 mL | 0.1729 mL | 0.3458 mL | 0.6917 mL | 0.8646 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Ciprofibrate is a peroxisome proliferator-activated receptor agonist.
- 3-Epicorosolic acid
Catalog No.:BCN5666
CAS No.:52213-27-1
- Lamalbid
Catalog No.:BCN3750
CAS No.:52212-87-0
- Tetrahydroberberine
Catalog No.:BCN2648
CAS No.:522-97-4
- Allo-Yohimbine
Catalog No.:BCN3487
CAS No.:522-94-1
- Dequalinium Chloride
Catalog No.:BCC4998
CAS No.:522-51-0
- Tetrahydrozoline HCl
Catalog No.:BCC4339
CAS No.:522-48-5
- Lochnerine
Catalog No.:BCN5667
CAS No.:522-47-4
- Norsanguinarine
Catalog No.:BCN3714
CAS No.:522-30-5
- Deguelin
Catalog No.:BCN4804
CAS No.:522-17-8
- Quercitrin
Catalog No.:BCN5665
CAS No.:522-12-3
- Evoxine
Catalog No.:BCN5664
CAS No.:522-11-2
- N'-Methylammodendrine
Catalog No.:BCN2147
CAS No.:52196-10-8
- Kaempferol-4'-O-beta-D-glucopyranoside
Catalog No.:BCN8130
CAS No.:52222-74-9
- Parathyroid hormone (1-34) (human)
Catalog No.:BCC1046
CAS No.:52232-67-4
- Isomucronulatol
Catalog No.:BCN1428
CAS No.:52250-35-8
- CGP 57380
Catalog No.:BCC5279
CAS No.:522629-08-9
- 3,5-Diprenyl-4-hydroxybenzaldehyde
Catalog No.:BCN4624
CAS No.:52275-04-4
- Ginsenoside Rf
Catalog No.:BCN1075
CAS No.:52286-58-5
- Ginsenoside Re
Catalog No.:BCN1073
CAS No.:52286-59-6
- Ginsenoside Rg2
Catalog No.:BCN1067
CAS No.:52286-74-5
- 4-Amino-2,5-dimethoxy-N-phenylbenzenesulphonamide
Catalog No.:BCC8676
CAS No.:52298-44-9
- Angelicin
Catalog No.:BCN5669
CAS No.:523-50-2
- Evolitrine
Catalog No.:BCN8350
CAS No.:523-66-0
- Flavoglaucin
Catalog No.:BCN6398
CAS No.:523-73-9
Development and validation of liquid chromatography-tandem mass spectrometric method for the quantification of ciprofibrate from human plasma.[Pubmed:24833347]
J Chromatogr Sci. 2015 Feb;53(2):219-25.
A new rapid, selective and sensitive liquid chromatography-tandem mass spectrometric method was developed and validated for the determination of Ciprofibrate, an antihyperlipidemic agent, in K2EDTA human plasma. Furosemide was used as internal standard (IS). The Ciprofibrate and IS were extracted using Oasis HLB 1 cc 30 mg solid-phase extraction cartridge. The chromatographic separation was performed on ACE C18, 50 x 4.6 mm, 5 microm column. The mobile phase consisted of 0.001% ammonia in methanol-acetonitrile-water (70:20:10, v/v/v). Detection and quantitation were performed by a triple quadrupole equipped with electrospray ionization and multiple reaction monitoring in negative ionization mode. The most intense [M-H](-) transition for Ciprofibrate at m/z 287.0 --> 85.0 and for IS at m/z 328.9.0 --> 204.9 were used for quantification. The method was found to linear over the range of 25-30,000 ng/mL (r > 0.998). The lower limit of quantitation (LLOQ) was 25 ng/mL. The extraction recovery was above 90%. The accuracy was found to be 101.26-106.44%. The stability testing was also investigated and it was found that both drug and IS were quite stable. The developed method was successfully applied to the bioequivalence study of Ciprofibrate 100 mg tablet after oral administration to healthy human volunteers.
Rhabdomyolysis as a clinical manifestation of association with ciprofibrate, sirolimus, cyclosporine, and pegylated interferon-alpha in liver-transplanted patients: a case report and literature review.[Pubmed:25131061]
Transplant Proc. 2014 Jul-Aug;46(6):1887-8.
BACKGROUND: Rhabdomyolysis is a syndrome characterized by impaired metabolic integrity of myocytes, causing the release of intracellular constituents into the circulation, and can be a serious side effect of drug intake. CASE REPORT: This report describes a unique case of rabdomyolysis secondary in which Ciprofibrate, sirolimus, cyclosporine, and pegylated interferon-alpha in a liver transplant patient was used. A 47-year-old male liver transplant recipient in 2009, who had hepatitis C and incidental hepatocellular carcinoma, underwent immunosuppressive therapy (cyclosporine and sirolimus). The patient is currently in treatment for viral recurrence with pegylated interferon-alpha and ribavirin; he had a history of hypertriglyceridemia treated with Ciprofibrate. He had development of severe and generalized myalgia and fever after the eighth application of pegylated interferon-alpha and increasing doses of cyclosporine. Laboratorial tests showed acute renal failure and significant increase in creatine kinase. Rhabdomyolysis secondary to interaction of fibrate-cyclosporine-pegylated interferon-alpha was postulated. CONCLUSIONS: Medical professionals should be aware of possible drug interactions and should monitor patients receiving these drugs.
A novel architecture based upon multi-walled carbon nanotubes and ionic liquid to improve the electroanalytical detection of ciprofibrate.[Pubmed:24919542]
Analyst. 2014 Aug 21;139(16):3961-7.
Voltammetric studies have been carried out using a glassy carbon electrode (GCE) modified with multi-walled carbon nanotubes (MWCNTs) and the ionic liquid 1-butyl-3-methylimidazolium chloride (IL). Studies on the electrochemical properties of GCEs modified with MWCNTs and IL within different polymeric films (dihexadecylphosphate (DHP), Nafion, and chitosan (CTS)) were performed using a [Fe(CN)6](4-/3-) electrochemical probe. The modified GCE with different polymeric films was also tested for Ciprofibrate (CPF) sensing in the presence and absence of IL in the film. The presence of IL and the MWCNTs improved the electrochemical response for CPF in all cases due to a synergic effect, and the IL-MWCNTs-DHP/GCE showed a great voltammetric profile for CPF detection. The IL-MWCNTs-DHP/GCE and differential pulse voltammetry (DPV) were used for the determination of CPF. An analytical curve was obtained for CPF in the concentration range of 2.50 x 10(-7) to 7.41 x 10(-6) mol L(-1) with a detection limit of 9.20 x 10(-8) mol L(-1). The proposed DPV method was successfully applied for CPF determination in pharmaceutical samples, and the results obtained agree with the results obtained using a spectrophotometric method at a confidence level of 95%.
